Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 0.69 |
| ▸ | DDB1 | Q16531 | 19/20 | 0.69 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.69 |
| ▸ | TNF | P01375 | 1/20 | 0.69 |
| ▸ | IL1B | P01584 | 1/20 | 0.69 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283120 | 0.93 | CRBN (0.68) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL18946147 | 0.92 | DDB1 (0.67) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL18509378 | 0.91 | CRBN (0.66) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL328520 | 0.91 | CRBN (0.66) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL19526118 | 0.90 | CRBN (0.67) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL26320556 | 0.89 | CRBN (0.63) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL282837 | 0.89 | CRBN (0.63) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL18900417 | 0.89 | CRBN (0.63) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL31316579 | 0.89 | CRBN (0.63) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL282858 | 0.89 | CRBN (0.62) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165095-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2024-05-23 | — | — | US | disclosed |
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220362229-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-11-17 | — | — | US | disclosed |
| EP-3820532-A2 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | H. Lee Moffitt Cancer Center & Research Institute, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| CN-112512589-A | Dimeric immunomodulatory compounds against CEREBLON-based mechanisms | H·李·莫菲特癌症中心研究有限公司 | 2021-03-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | CRBN, CD4, CD74 | CRBN 1/4885DDB1 1404/4885IKZF3 327/4885 |
| US-20220362229-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | CRBN, CD4, CD74 | CRBN 1/4885DDB1 1404/4885IKZF3 327/4885 |
| US-20240165095-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | CRBN, CD4, CD74 | CRBN 1/4885DDB1 1404/4885IKZF3 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.